Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate‐pair sequencing

We used high resolution mate‐pair sequencing (HRMPS) in 15 patients with primary myelofibrosis (PMF): eight with normal karyotype and seven with PMF‐characteristic cytogenetic abnormalities, including der(6)t(1;6)(q21–23;p21.3) (n = 4), der(7)t(1;7)(q10;p10) (n = 2), del(20)(q11.2q13.3) (n = 3), and complex karyotype (n = 1). We describe seven novel deletions/translocations in five patients (including two with normal karyotype) whose breakpoints were PCR‐validated and involved MACROD2, CACNA2D4, TET2, SGMS2, LRBA, SH3D19, INTS3, FOP (CHTOP), SCLT1, and PHF17. Deletions with breakpoints involving MACROD2 (lysine deacetylase; 20p12.1) were recurrent and found in two of the 15 study patients. A novel fusion transcript was found in one of the study patients (INTS3‐CHTOP), and also in an additional non‐study patient with PMF. In two patients with der(6)t(1;6)(q21–23;p21.3), we were able to map the precise translocation breakpoints, which involved KCNN3 and GUSBP2 in one case and HYDIN2 in another. This study demonstrates the utility of HRMPS in uncovering submicroscopic deletions/translocations/fusions, and precise mapping of breakpoints in those with overt cytogenetic abnormalities. The overall results confirm the genetic heterogeneity of PMF, given the low frequency of recurrent specific abnormalities, identified by this screening strategy. Currently, we are pursuing the pathogenetic relevance of some of the aforementioned findings. Am. J. Hematol. 88:741–746, 2013. © 2013 Wiley Periodicals, Inc.

[1]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[2]  R. Laborde,et al.  SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML , 2013, Leukemia.

[3]  A. Tefferi,et al.  SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. , 2012, Blood.

[4]  David I. Smith,et al.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. , 2012, Blood.

[5]  A. Tefferi,et al.  SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.

[6]  Bodo Grimbacher,et al.  Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. , 2012, American journal of human genetics.

[7]  A. Tefferi,et al.  Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management , 2012, American journal of hematology.

[8]  A. Tefferi,et al.  TP53 mutations and polymorphisms in primary myelofibrosis , 2011, American journal of hematology.

[9]  A. Tefferi,et al.  IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F , 2011, Leukemia.

[10]  A. Tefferi Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management , 2011, American journal of hematology.

[11]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[12]  A. Tefferi,et al.  Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post‐polycythemia vera myelofibrosis , 2011, American journal of hematology.

[13]  A. Tefferi Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up? , 2011, Leukemia.

[14]  O. Abdel-Wahab,et al.  DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms , 2011, Leukemia.

[15]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  John M Denu,et al.  Identification of Macrodomain Proteins as Novel O-Acetyl-ADP-ribose Deacetylases* , 2011, The Journal of Biological Chemistry.

[17]  David I. Smith,et al.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. , 2011, Blood.

[18]  D. Gilliland,et al.  Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms , 2010, Leukemia.

[19]  A. Tefferi,et al.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.

[20]  X. Guan,et al.  Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma , 2010, Acta Pharmacologica Sinica.

[21]  A. Tefferi,et al.  LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations , 2010, Leukemia.

[22]  M. Cazzola,et al.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms , 2010, Leukemia.

[23]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[24]  O. Abdel-Wahab,et al.  Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms , 2009, American journal of hematology.

[25]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[26]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[27]  R. Mesa,et al.  Karyotype complements the International Prognostic Scoring System for primary myelofibrosis , 2009, European journal of haematology.

[28]  D. Gilliland,et al.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.

[29]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[30]  A. Hall,et al.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.

[31]  Eric W. Klee,et al.  Quantitating tissue specificity of human genes to facilitate biomarker discovery , 2007, Bioinform..

[32]  J. Weber,et al.  A 360-kb interchromosomal duplication of the human HYDIN locus. , 2006, Genomics.

[33]  J. Reilly,et al.  Der(6)t(1;6)(q21–23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia , 2005, British journal of haematology.

[34]  Han Liu,et al.  Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein , 2004, Oncogene.

[35]  Chi Wai So,et al.  Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein. , 2004, Blood.

[36]  B. Druker,et al.  Perspectives on the development of a molecularly targeted agent. , 2002, Cancer cell.